Angelini Pharma, an Italian pharmaceutical company, announced on Thursday its agreement to acquire Catalyst Pharmaceuticals, a Florida-based firm focused on rare diseases, for approximately $4.1 billion in cash.
The acquisition values Catalyst at $31.50 per share, a 28% premium over the company’s stock price during the 30-day period prior to April 22. This date marks when news of the potential deal became publicly known.
Catalyst Pharmaceuticals currently markets three approved medications, and its acquisition will provide Angelini Pharma with a significant entry into the U.S. pharmaceutical market. Additionally, the deal strengthens Angelini’s existing focus on neurology.
Related articles
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...
Kyle Diamantas Named Acting FDA Commissioner Amid Biotech Sector Optimism
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their...
Rare Gene Therapy Side Effect: Toddler Develops Tumor Linked to Treatment
When 13-month-old Adam’s stem cell transplant failed, doctors had two options: A second transplant, which they warned carried a 10% to 15% risk of dea...